The present invention is directed to 13C and/or 2H isotope enhanced ambroxol (“isotope enhanced ambroxol”) and its use in the treatment of autophagy infections, especially mycobacterial and other infections, disease states and/or conditions of the lung, such as tuberculosis, especially including drug resistant and multiple drag resistant tuberculosis. Pharmaceutical compositions comprising isotope enhanced ambroxol, alone or in combination with an additional bioactive agent, especially rifamycin antibiotics, including an additional autophagy modulator (an agent which is active to promote or inhibit autophagy), thus being useful against, an autophagy mediated disease state and/or condition), especially an autophagy mediated disease state and/or condition which occurs in the lungs, for example, a Mycobacterium infection. Chronic Obstructive Pulmonary Disease (COPD), asthma, pulmonary fibrosis, cystic fibrosis, Sjogren's disease and lung cancer (small cell and non-small cell lung cancer, among other disease states and/or conditions, especially of the lung. Methods of treating autophagy disease states and/or conditions, especially including autophagy disease states or conditions which occur principally in the lungs of a patient represent a further embodiment of the present invention. An additional embodiment includes methods of synthesizing compounds according to the present invention as otherwise disclosed herein.La présente invention concerne de l'ambroxol à isotope 13C et/ou 2H amélioré ("ambroxol à isotope amélioré") et son utilisation dans le traitement d'infections par autophagie, en particulier des infections mycobactériennes ainsi que d'autres infections, des états pathologiques et/ou des affections du poumon, tels que la tuberculose, comprenant notamment, la tuberculose pharmacorésistante et la tuberculose multirésistante aux médicaments. L'invention concerne également des compositions pharmaceutiques comprenant de l'ambroxol à isotope amélioré, seul ou en comb
